PMID- 37354221
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230701
IS  - 2730-6011 (Electronic)
IS  - 2730-6011 (Linking)
VI  - 14
IP  - 1
DP  - 2023 Jun 24
TI  - Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric 
      cancer.
PG  - 111
LID - 10.1007/s12672-023-00731-1 [doi]
LID - 111
AB  - PURPOSE: This study aimed to elucidate the clinicopathological characteristics of 
      alpha-fetoprotein (AFP)-producing gastric carcinoma (AFP-GC) with human epidermal 
      growth factor receptor (HER)2 overexpression to extend the treatment strategy for 
      AFP-GC. METHODS: We analyzed 41 patients with AFP-GC who underwent surgical 
      resection or chemotherapy from 1989 to 2019, and who had over 20ng/mL of serum 
      AFP or positive immunohistochemical AFP expression. HER2 expression status was 
      investigated by immunohistochemistry (IHC) for all patients and by fluorescence 
      in situ hybridization (FISH) for cases with an IHC score of 2+. AFP-GC with an 
      IHC score of 3 + or 2 + and FISH positivity was defined as HER2 overexpressed 
      AFP-GC. The correlation between HER2 status and clinicopathological 
      characteristics and prognosis in AFP-GC was analyzed. RESULTS: HER2 
      overexpression was detected in 17.1% of AFP-GC patients. The prognosis of the 
      patients with HER2 overexpressed AFP-GC was not significantly different compared 
      to HER2 non-overexpressed AFP-GC. HER2 overexpressed AFP-GC consisted of 
      heterogeneous histology with a higher proportion of mixed-type tumors 
      (p = 0.002). The clinical outcome of AFP-GC with mixed-type of histology tended 
      to be better than other intestinal or diffuse types (p = 0.05). CONCLUSION: HER2 
      overexpressed AFP-GC consisted of a mixed type of histology, which showed a 
      better prognosis. The results presented that HER2 status in AFP-GC is one of the 
      molecular candidates to improve the prognosis.
CI  - (c) 2023. The Author(s).
FAU - Shimizu, Hiroko
AU  - Shimizu H
AD  - Division of Digestive Surgery, Department of Surgery, Nihon University School of 
      Medicine, Tokyo, Japan.
FAU - Kochi, Mitsugu
AU  - Kochi M
AD  - Division of Digestive Surgery, Department of Surgery, Nihon University School of 
      Medicine, Tokyo, Japan.
FAU - Fujii, Masashi
AU  - Fujii M
AD  - Japan Clinical Cancer Research Organization, Tokyo, Japan.
FAU - Watabe, Megumu
AU  - Watabe M
AD  - Division of Digestive Surgery, Department of Surgery, Nihon University School of 
      Medicine, Tokyo, Japan.
FAU - Matsuno, Yoritaka
AU  - Matsuno Y
AD  - Division of Digestive Surgery, Department of Surgery, Nihon University School of 
      Medicine, Tokyo, Japan.
FAU - Kawai, Takaharu
AU  - Kawai T
AD  - Division of Digestive Surgery, Department of Surgery, Nihon University School of 
      Medicine, Tokyo, Japan.
FAU - Suda, Hiroshi
AU  - Suda H
AD  - Division of Digestive Surgery, Department of Surgery, Nihon University School of 
      Medicine, Tokyo, Japan.
FAU - Tanino, Tomoyuki
AU  - Tanino T
AD  - Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon 
      University School of Medicine, Tokyo, Japan.
FAU - Nakanishi, Yoko
AU  - Nakanishi Y
AD  - Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon 
      University School of Medicine, Tokyo, Japan. nakanishi.youko@nihon-u.ac.jp.
AD  - Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon 
      University School of Medicine, 30-1 Ohyaguchi-Kamicho, Itabashi-ku, Tokyo, 
      173-8610, Japan. nakanishi.youko@nihon-u.ac.jp.
FAU - Masuda, Shinobu
AU  - Masuda S
AD  - Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon 
      University School of Medicine, Tokyo, Japan.
FAU - Okamura, Yukiyasu
AU  - Okamura Y
AD  - Division of Digestive Surgery, Department of Surgery, Nihon University School of 
      Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230624
PL  - United States
TA  - Discov Oncol
JT  - Discover oncology
JID - 101775142
PMC - PMC10290623
OTO - NOTNLM
OT  - AFP-producing gastric cancer
OT  - HER2
OT  - Mixed histological subtype
COIS- The authors declare that they have no competing interests.
EDAT- 2023/06/24 21:03
MHDA- 2023/06/24 21:04
PMCR- 2023/06/24
CRDT- 2023/06/24 11:03
PHST- 2023/03/29 00:00 [received]
PHST- 2023/06/16 00:00 [accepted]
PHST- 2023/06/24 21:04 [medline]
PHST- 2023/06/24 21:03 [pubmed]
PHST- 2023/06/24 11:03 [entrez]
PHST- 2023/06/24 00:00 [pmc-release]
AID - 10.1007/s12672-023-00731-1 [pii]
AID - 731 [pii]
AID - 10.1007/s12672-023-00731-1 [doi]
PST - epublish
SO  - Discov Oncol. 2023 Jun 24;14(1):111. doi: 10.1007/s12672-023-00731-1.